Evidence map›Paper›PMID 42533093›Full record

ArticleEuropean journal of human genetics : EJHG2026

BRCA1 and BRCA2 population screening in Latvia: feasibility, engagement, and early lessons from a pilot study.

Arvids Irmejs, Zanda Daneberga, Kristine Kiploka, Marta Augucevica, Anneta Cerneikina, Linda Gailite, Agate Kalcenaua, Ilva Kononova, Emil Syundyukov, Edvins Miklasevics and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Arvids IrmejsInstitute of Oncology and Molecular Genetics, Riga Stradins University, Riga, Latvia. arvids.irmejs@rsu.lv.ORCID http://orcid.org/0000-0002-0538-1194
Zanda DanebergaInstitute of Oncology and Molecular Genetics, Riga Stradins University, Riga, Latvia.ORCID http://orcid.org/0000-0003-0887-2973
Kristine KiplokaInstitute of Oncology and Molecular Genetics, Riga Stradins University, Riga, Latvia.
Marta AugucevicaPauls Stradins Clinical University Hospital, Riga, Latvia.
Anneta CerneikinaInstitute of Oncology and Molecular Genetics, Riga Stradins University, Riga, Latvia.
Linda GailiteInstitute of Oncology and Molecular Genetics, Riga Stradins University, Riga, Latvia.
Agate KalcenauaLongenesis, Riga, Latvia.
Ilva KononovaLongenesis, Riga, Latvia.
Emil SyundyukovLongenesis, Riga, Latvia.ORCID http://orcid.org/0000-0001-7456-7366
Edvins MiklasevicsInstitute of Oncology and Molecular Genetics, Riga Stradins University, Riga, Latvia.
Cathrine BjorvatnWestern Norway Familial Cancer Center, Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway.
Hildegunn Høberg VettiEuropean Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS), Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-9876-576X
Janis GardovskisInstitute of Oncology and Molecular Genetics, Riga Stradins University, Riga, Latvia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pathogenic variants in BRCA1 and BRCA2 account for the majority of hereditary breast and ovarian cancer (HBOC) cases, and are associated with substantial morbidity, mortality, and economic burden. Population screening for BRCA1 and BRCA2 pathogenic variants (PVs) may enable cancer prevention and reduce downstream costs and mortality. The feasibility pilot of BRCA1 and BRCA2 PV population screening in Latvia was conducted among cancer-free females aged 25-59 years, using digital recruitment tools and saliva-based BRCA1 and BRCA2 gene NGS with CNV analysis. Psychological impact was assessed using PHQ-9 and GAD-7. After 3,438 email invitations and media campaigns, 536 participants provided samples. Eight PVs were identified, and all carriers reported at least one affected first-degree relative. PHQ-9 and GAD-7 scores showed no significant pre- and post-testing differences. Saliva-based population screening for BRCA1 and BRCA2 pathogenic variants is feasible in Latvia showing considerable (1.5%) frequency of PVs, acceptable psychological outcomes, but requires improved engagement strategies and equitable access pathways.

Identifiers

PMID42533093

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.